Polycaprolactone-based dermal filler complications: A retrospective study of 1111 treatments.

Background: Aging signs can be corrected through volume restoration in multiple soft tissue layers and in the supraperiosteal plane using hyaluronic acid (HA) or nonhyaluronic acid (non-HA) fillers. The non-HA bioresorbable polycaprolactone (PCL)-based filler with collagen-stimulating properties has a proven safety profile, but rare potential complications such as nodules and granuloma can occur. Furthermore, PCL-based fillers cannot be immediately removed by injection of an enzyme.

Polycaprolactone facial volume restoration of a 46-year-old Asian women: A case report.

A 46-year-old Asian women was treated with a next-generation bioresorbable biostimulatory polycaprolactone (PCL)-based dermal filler to restore facial volume loss. Before- and after (12 weeks of follow-up)-treatment photographs were analyzed and compared. In addition, before- and after-treatment contour images were recorded using the Vectra XT 3D imaging system (Canfield Scientific, Inc.

Recommendations for volume augmentation and rejuvenation of the face and hands with the new generation polycaprolactone-based collagen stimulator (Ellansé).

Background: The range of fillers currently available for soft-tissue augmentation is constantly expanding. The latest advances in filler technology include collagen biostimulators that exert their esthetic effect by promoting neocollagenesis. One such product is the next-generation collagen biostimulator (Ellansé) that demonstrates properties as yet unseen in soft-tissue fillers.